Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
41 Age-Related Macular Degeneration Trials near Phoenix, AZ
Power is an online platform that helps thousands of Age-Related Macular Degeneration patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerEYP-1901 vs Aflibercept for Age-Related Macular Degeneration
Phoenix, ArizonaThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Subfoveal Fibrosis, Atrophy, Scarring, Others
Must Be Taking:Anti-VEGF Injections
400 Participants Needed
EYP-1901 for Age-Related Macular Degeneration
Phoenix, ArizonaThis is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Subfoveal Fibrosis, Atrophy, Scarring, Others
Must Be Taking:Anti-VEGF Injections
400 Participants Needed
Elamipretide for Age-Related Macular Degeneration
Phoenix, ArizonaThe goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:55+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetic Retinopathy, Organ Transplant, Cancer, Others
Must Not Be Taking:Plaquenil, Tamoxifen, Digoxin, Others
360 Participants Needed
Axitinib Implant for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a small device placed in the eye that releases medication for patients with a severe form of AMD. The medication helps stop abnormal blood vessel growth in the eye, potentially preventing further vision loss. This approach has significantly improved treatment for this condition in recent years.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
344 Participants Needed
RGX-314 Gene Therapy for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
660 Participants Needed
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
Must Be Taking:Anti-VEGF
540 Participants Needed
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Ocular Diseases, Uncontrolled Hypertension, Others
Must Be Taking:Anti-VEGF Injections
1000 Participants Needed
4D-150 for Age-Related Macular Degeneration
Phoenix, ArizonaPhase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uveitis, Photodynamic Therapy, Others
Must Be Taking:Anti-VEGF
215 Participants Needed
RGX-314 for Age-Related Macular Degeneration
Phoenix, ArizonaThis is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 in their study eye. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early termination visit in the previous (parent) clinical study. Participants will be followed for up to 5 years post-RGX-314 administration (inclusive of the parent study). After enrollment and a 6-month follow-up visit, participants will attend at least annual study visits through the end of the 5-year post-RGX-314 administration follow-up period.
Additionally, an interventional fellow eye treatment substudy will evaluate the safety, efficacy, and immunogenicity of subretinal RGX-314 administration in the fellow eye of participants having bilateral disease who previously received a subretinal injection of RGX-314 in their study eye. Participants who qualify for the substudy will receive subretinal administration of RGX-314 in their fellow eye and complete 13 study visits in a 54-week period. Following completion of the substudy participants will continue in the observational portion of the study for up to 5 years post RGX-314 administration in their fellow eye.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:50+
Sex:All
865 Participants Needed
Zifibancimig for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Vitrectomy, Glaucoma, Uveitis, Others
Must Be Taking:Anti-VEGF
251 Participants Needed
Gene Therapy for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a new gene therapy called KH631 for patients with a severe eye condition known as neovascular AMD. The therapy uses a harmless virus to deliver a protein that blocks a harmful substance in the eye. This could help improve vision and reduce the need for frequent eye injections.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:50 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Tears, Vitreous Hemorrhage, Others
Must Be Taking:Anti-VEGF
25 Participants Needed
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best corrected distance visual acuity \>2 lines from pre-surgery baseline level).
The study will test the null hypothesis that the percentage of patients who experience persistent vision-impairing corneal edema is \>17% against the alternative that the percentage is \<17%. The null hypothesis will be rejected if the upper bound of the two-sided 95% confidence integral for the observed percentage is \<17%.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:65+
Sex:All
770 Participants Needed
This trial is testing a new treatment called JNJ-81201887 to see if it can slow down the growth of damaged areas in the eyes of people with geographic atrophy. This condition causes parts of the retina to deteriorate, and the treatment aims to protect the retina and preserve vision.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60+
Sex:All
305 Participants Needed
BI 771716 for Age-Related Macular Degeneration
Phoenix, ArizonaThis study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.
Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Exudative AMD, Uncontrolled Glaucoma, Others
180 Participants Needed
BI 1584862 for Age-Related Macular Degeneration
Phoenix, ArizonaThis study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF) and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55+
Sex:All
Key Eligibility Criteria
Disqualifiers:Exudative AMD, Uncontrolled Glaucoma, Others
Must Not Be Taking:IVT Treatments, Investigational Oral
138 Participants Needed
Danicopan for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a medication called danicopan to see if it can help people with a specific type of eye disease called Geographic Atrophy, which is related to Age-related Macular Degeneration. The study will check how well the medication works, how safe it is, and how the body handles it.
Trial Details
Trial Status:Active Not Recruiting
Age:60+
Sex:All
365 Participants Needed
Tarcocimab + Tabirafusp for Wet Age-Related Macular Degeneration
Phoenix, ArizonaA Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Monocular, Fibrosis, Atrophy, Others
675 Participants Needed
Axitinib Implant for Age-Related Macular Degeneration
Phoenix, ArizonaStudy to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Monocular, Scar, Fibrosis, Atrophy, Others
Must Be Taking:Aflibercept
825 Participants Needed
RBS-001 vs Eylea for Age-Related Macular Degeneration
Phoenix, ArizonaThis clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
434 Participants Needed
SAR402663 for Macular Degeneration
Phoenix, ArizonaThis is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration.
Participants will be enrolled in one of 2 parts:
* In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants
* In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from Part I. Participants and investigators will be masked to dose.
After receiving one-time dose of SAR402663, participants will undergo regular assessments over 12 months. Following this, participants will enter an extended follow-up (EFU) phase for the assessment of safety and durability of clinical activity of SAR402663 through Year 5.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Glaucoma, Uveitis, Infections, Others
Must Be Taking:Anti-VEGF
66 Participants Needed
AR-14034 for Age-Related Macular Degeneration
Phoenix, ArizonaThe primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Ocular Disease, Glaucoma, Hypertension, Others
Must Be Taking:Ocular Anti-VEGF
140 Participants Needed
Pozelimab + Cemdisiran for Macular Degeneration
Phoenix, ArizonaThis study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atrophy (GA) caused by age-related macular degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead).
The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug(s)
* How much study drug(s) are in the blood at different times
* Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetic Retinopathy, Macular Edema, Others
Must Be Taking:Meningococcal, Pneumococcal Vaccines
750 Participants Needed
RGX-314 Gene Therapy for Age-Related Macular Degeneration
Phoenix, ArizonaRGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to twelve weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Glaucoma, Others
Must Be Taking:Anti-VEGF
115 Participants Needed
Pegcetacoplan for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a medication called pegcetacoplan to see if it is safe and effective for people with a severe eye condition called geographic atrophy, which is related to age-related macular degeneration. The medication aims to protect the eye by blocking harmful immune responses. Pegcetacoplan has shown an acceptable safety profile in previous studies for geographic atrophy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60+
Sex:All
1200 Participants Needed
4D-150 + EYLEA for Age-Related Macular Degeneration
Phoenix, ArizonaA Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Retinal Detachment, Glaucoma, Uncontrolled Blood Pressure, Others
400 Participants Needed
AVD-104 for Age-Related Macular Degeneration
Phoenix, ArizonaInvestigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 90
Sex:All
300 Participants Needed
Microcurrent Stimulation for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial evaluates a therapy that uses tiny electrical currents through the eyelid to help patients with dry age-related macular degeneration. The goal is to improve eye health by stimulating eye tissues.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50 - 100
Sex:All
95 Participants Needed
HLX04-O vs Ranibizumab for Wet Age-Related Macular Degeneration
Phoenix, ArizonaThis study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Age:50+
Sex:All
388 Participants Needed
ANX007 for Age-Related Macular Degeneration
Scottsdale, ArizonaThe primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Stargardt Disease, Cone-rod Dystrophy, Others
630 Participants Needed
Tinlarebant for Age-Related Macular Degeneration
Phoenix, ArizonaThis trial is testing a new pill called tinlarebant in people with Geographic Atrophy, an eye condition that causes vision loss. The goal is to see if the pill can help slow down or stop the progression of the disease.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Diabetic Macular Edema, Retinopathy, Glaucoma, Others
429 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Age-Related Macular Degeneration clinical trials in Phoenix, AZ pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Age-Related Macular Degeneration clinical trials in Phoenix, AZ work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Age-Related Macular Degeneration trials in Phoenix, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Phoenix, AZ for Age-Related Macular Degeneration is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Phoenix, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Age-Related Macular Degeneration medical study in Phoenix, AZ ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Age-Related Macular Degeneration clinical trials in Phoenix, AZ ?
Most recently, we added RBS-001 vs Eylea for Age-Related Macular Degeneration, 4D-150 + EYLEA for Age-Related Macular Degeneration and Ixo-vec + Aflibercept for Age-Related Macular Degeneration to the Power online platform.